Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2008

Open Access 01-12-2008 | Review

Inflammaging as a prodrome to Alzheimer's disease

Authors: Brian Giunta, Francisco Fernandez, William V Nikolic, Demian Obregon, Elona Rrapo, Terrence Town, Jun Tan

Published in: Journal of Neuroinflammation | Issue 1/2008

Login to get access

Abstract

Recently, the term "inflammaging" was coined by Franceshci and colleagues to characterize a widely accepted paradigm that ageing is accompanied by a low-grade chronic up-regulation of certain pro-inflammatory responses. Inflammaging differs significantly from the traditional five cardinal features of acute inflammation in that it is characterized by a relative decline in adaptive immunity and T-helper 2 responses and is associated with increased innate immunity by cells of the mononuclear phagocyte lineage. While the over-active innate immunity characteristic of inflammaging may remain subclinical in many elderly individuals, a portion of individuals (postulated to have a "high responder inflammatory genotype") may shift from a state of "normal" or "subclinical" inflammaging to one or more of a number of age-associated diseases. We and others have found that IFN-γ and other pro-inflammatory cytokines interact with processing and production of Aβ peptide, the pathological hallmark feature of Alzheimer's disease (AD), suggesting that inflammaging may be a "prodrome" to AD. Although conditions of enhanced innate immune response with overproduction of pro-inflammatory proteins are associated with both healthy aging and AD, it is suggested that those who age "well" demonstrate anti-inflammaging mechanisms and biomarkers that likely counteract the adverse immune response of inflammaging. Thus, opposing the features of inflammaging may prevent or treat the symptoms of AD. In this review, we fully characterize the aging immune system. In addition, we explain how three novel treatments, (1) human umbilical cord blood cells (HUCBC), (2) flavanoids, and (3) Aβ vaccination oppose the forces of inflammaging and AD-like pathology in various mouse models.
Literature
1.
Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, Panourgia MP, Invidia L, Celani L, Scurti M, Cevenini E, Castellani GC, Salvioli S: Inflammaging and anti-inflammaging: A systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev. 2007, 128: 92-105. 10.1016/j.mad.2006.11.016.PubMed
2.
Salvioli S, Capri M, Valensin S, Tieri P, Monti D, Ottaviani E, Franceschi C: Inflamm-aging, cytokines and aging: State of the art, new hypotheses on the role of mitochondria and new perspectives from systems biology. Curr Pharm Des. 2006, 12: 3161-3171. 10.2174/138161206777947470.PubMed
3.
De Martinis M, Franceschi C, Monti D, Ginaldi L: Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett. 2005, 579: 2035-2039. 10.1016/j.febslet.2005.02.055.PubMed
4.
Fagiolo U, Cossarizza A, Scala E, Fanales-Belasio E, Ortolani C, Cozzi E, Monti D, Franceschi C, Paganelli R: Increased cytokine production in mononuclear cells of healthy elderly people. Eur J Immunol. 1993, 23: 2375-2378. 10.1002/eji.1830230950.PubMed
5.
Franceschi C, Monti D, Sansoni P, Cossarizza A: The immunology of exceptional individuals: The lesson of centenarians. Immunol Today. 1995, 16: 12-16. 10.1016/0167-5699(95)80064-6.PubMed
6.
Lio D, Scola L, Crivello A, Colonna-Romano G, Candore G, Bonafé M, Cavallone L, Marchegiani F, Olivieri F, Franceschi C, Caruso C: Inflammation, genetics, and longevity: Further studies on the protective effects in men of IL-10-1082 promoter SNP and its interaction with TNF-alpha -308 promoter SNP. J Med Genet. 2003, 40: 296-299. 10.1136/jmg.40.4.296.PubMedCentralPubMed
7.
Candore G, Colonna-Romano G, Balistreri CR, Di Carlo D, Grimaldi MP, Listì F, Nuzzo D, Vasto S, Lio D, Caruso C: Biology of longevity: Role of the innate immune system. Rejuvenation Res. 2006, 9: 143-148. 10.1089/rej.2006.9.143.PubMed
8.
Vasto S, Candore G, Balistreri CR, Caruso M, Colonna-Romano G, Grimaldi MP, Listi F, Nuzzo D, Lio D, Caruso C: Inflammatory networks in ageing, age-related diseases and longevity. Mech Ageing Dev. 2007, 128: 83-91. 10.1016/j.mad.2006.11.015.PubMed
9.
Giunta S: Is inflammaging an auto[innate]immunity subclinical syndrome?. Immun Ageing. 2006, 3: 12-10.1186/1742-4933-3-12.PubMedCentralPubMed
10.
Bruunsgaard H, Skinhoj P, Qvist J, Pedersen BK: Elderly humans show prolonged in vivo inflammatory activity during pneumococcal infections. J Infect Dis. 1999, 180: 551-554. 10.1086/314873.PubMed
11.
Bruunsgaard H, Pedersen BK: The senile immune system. Ugeskr Laeger. 1999, 16: 4740-4743.
12.
Bruunsgaard H, Andersen-Ranberg K, Jeune B, Pedersen AN, Skinhøj P, Pedersen BK: A high plasma concentration of TNF-alpha is associated with dementia in centenarians. J Gerontol A Biol Sci Med Sci. 1999, 54: M357-64.PubMed
13.
Zanni F, Vescovini R, Biasini C, Fagnoni F, Zanlari L, Telera A, Di Pede P, Passeri G, Pedrazzoni M, Passeri M, Franceschi C, Sansoni P: Marked increase with age of type 1 cytokines within memory and effector/cytotoxic CD8+ T cells in humans: A contribution to understand the relationship between inflammation and immunosenescence. Exp Gerontol. 2003, 38: 981-987. 10.1016/S0531-5565(03)00160-8.PubMed
14.
Giacconi R, Cipriano C, Albanese F, Boccoli G, Saba V, Olivieri F, Franceschi C, Mocchegiani E: The -174G/C polymorphism of IL-6 is useful to screen old subjects at risk for atherosclerosis or to reach successful ageing. Exp Gerontol. 2004, 39: 621-628. 10.1016/j.exger.2003.12.013.PubMed
15.
Wikby A, Nilsson BO, Forsey R, Thompson J, Strindhall J, Löfgren S, Ernerudh J, Pawelec G, Ferguson F, Johansson B: The immune risk phenotype is associated with IL-6 in the terminal decline stage: Findings from the swedish NONA immune longitudinal study of very late life functioning. Mech Ageing Dev. 2006, 127: 695-704. 10.1016/j.mad.2006.04.003.PubMed
16.
Mannucci PM, Mari D, Merati G, Peyvandi F, Tagliabue L, Sacchi E, Taioli E, Sansoni P, Bertolini S, Franceschi C: Gene polymorphisms predicting high plasma levels of coagulation and fibrinolysis proteins. A study in centenarians. Arterioscler Thromb Vasc Biol. 1997, 17: 755-759.PubMed
17.
Mari D, Mannucci PM, Coppola R, Bottasso B, Bauer KA, Rosenbergm R: Hypercoagulability in centenarians: The paradox of successful aging. Blood. 1995, 85: 3144-3149.PubMed
18.
Coppola R, Mari D, Lattuada A, Franceschi C: Von willebrand factor in italian centenarians. Haematologica. 2003, 88: 39-43.PubMed
19.
Bonfigli AR, Sirolla C, Cenerelli S, Marra M, Boemi M, Franceschi C, Testa I, Mari D, Sacchi E, Testa R: Plasminogen activator inhibitor-1 plasma level increases with age in subjects with the 4G allele at position -675 in the promoter region. Thromb Haemost. 2004, 92: 1164-1165.PubMed
20.
Bonafe M, Olivieri F, Cavallone L, Giovagnetti S, Mayegiani F, Cardelli M, Pieri C, Marra M, Antonicelli R, Lisa R, Rizzo MR, Paolisso G, Monti D, Franceschi C: A gender–dependent genetic predisposition to produce high levels of IL-6 is detrimental for longevity. Eur J Immunol. 2001, 31: 2357-2361. 10.1002/1521-4141(200108)31:8<2357::AID-IMMU2357>3.0.CO;2-X.PubMed
21.
Cipriano C, Caruso C, Lio D, Giacconi R, Malavolta M, Muti E, Gasparini M, Franceschi C, Mocchegiani E: The -308G/A polymorphism of TNF-alpha influences immunological parameters in old subjects affected by infectious diseases. Int J Immunogenet. 2005, 32: 13-18. 10.1111/j.1744-313X.2005.00490.x.PubMed
22.
Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, De Benedictis G: Inflamm-aging. an evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000, 908: 244-254.PubMed
23.
Aspinall R, Andrew D: Immunosenescence: Potential causes and strategies for reversal. Biochem Soc Trans. 2000, 28: 250-254.PubMed
24.
Aspinall R: Longevity and the immune response. Biogerontology. 2000, 1: 273-278. 10.1023/A:1010046532657.PubMed
25.
Linton PJ, Li SP, Zhang Y, Bautista B, Huynh Q, Trinh T, Linton PJ: Intrinsic versus environmental influences on T-cell responses in aging. Immunol Rev. 2005, 205: 207-219. 10.1111/j.0105-2896.2005.00266.x.PubMed
26.
Allman D, Miller JP: B cell development and receptor diversity during aging. Curr Opin Immunol. 2005, 17: 463-467.PubMed
27.
Effros RB, Dagarag M, Spaulding C, Man J: The role of CD8+ T-cell replicative senescence in human aging. Immunol Rev. 2005, 205: 147-157. 10.1111/j.0105-2896.2005.00259.x.PubMed
28.
Pawelec G: When T cells get old. Sci Aging Knowledge Environ. 2005, 2005 (50): pe39-10.1126/sageke.2005.50.pe39.PubMed
29.
Fann M, Chiu WK, Wood WH, Levine BL, Becker KG, Weng NP: Gene expression characteristics of CD28null memory phenotype CD8+ T cells and its implication in T-cell aging. Immunol Rev. 2005, 205: 190-206. 10.1111/j.0105-2896.2005.00262.x.PubMed
30.
Weng NP: Aging of the immune system: How much can the adaptive immune system adapt?. Immunity. 2006, 24: 495-499. 10.1016/j.immuni.2006.05.001.PubMedCentralPubMed
31.
Cossarizza A, Ortolani C, Paganelli R, Barbieri D, Monti D, Sansoni P, Fagiolo U, Castellani G, Bersani F, Londei M, Franceschi C: CD45 isoforms expression on CD4+ and CD8+ T cells throughout life, from newborns to centenarians: Implications for T cell memory. Mech Ageing Dev. 1996, 86: 173-195. 10.1016/0047-6374(95)01691-0.PubMed
32.
Solana R, Pawelec G, Tarazona R: Aging and innate immunity. Immunity. 2006, 24: 491-494. 10.1016/j.immuni.2006.05.003.PubMed
33.
Tarazona R, DelaRosa O, Alonso C, Ostos B, Espejo J, Pena J, Solana R: Increased expression of NK cell markers on T lymphocytes in aging and chronic activation of the immune system reflects the accumulation of effector/senescent T cells. Mech Ageing Dev. 2000, 121: 77-88. 10.1016/S0047-6374(00)00199-8.PubMed
34.
Khan N, Shariff N, Cobbold M, Bruton R, Ainsworth JA, Sinclair AJ, Nayak L, Moss PA: Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol. 2002, 169: 1984-1992.PubMed
35.
Koch S, Solana R, Dela Rosa O, Pawelec G: Human cytomegalovirus infection and T cell immunosenescence: A mini review. Mech Ageing Dev. 2006, 127: 538-543. 10.1016/j.mad.2006.01.011.PubMed
36.
Ouyang Q, Wagner WM, Voehringer D, Wikby A, Klatt T, Walter S, Muller CA, Pircher H, Pawelec G: Age-associated accumulation of CMV-specific CD8+ T cells expressing the inhibitory killer cell lectin-like receptor G1 (KLRG1). Exp Gerontol. 2003, 38: 911-920. 10.1016/S0531-5565(03)00134-7.PubMed
37.
Vsecovini R, Telera A, Fagnoni FF, Biasini C, Medici MC, Valcavi P, di Pede P, Lucchini G, Zanlari L, Passeri G, Zanni F, Chezzi C, Franchesci C, Sansoni P: Different contribution of EBV and CMV infections in very long-term carriers to age-related alterations of CD8+ T cells. Exp Gerontol. 2004, 39: 1233-1243. 10.1016/j.exger.2004.04.004.
38.
Ouyang Q, Wanger WM, Wikby A, Walter S, Aubert G, Dodi AI, Travers P, Pawelec G: Large numbers of dysfunctional CD8+ T lymphocytes bearing receptors for a single dominant CMV epitope in the very old. J Clin Immunol. 2003, 23: 247-257. 10.1023/A:1024580531705.PubMed
39.
Franceschi C, Valensin S, Fagnoni F, Barbi C, Bonafe M: Biomarkers of immunosenescence within an evolutionary perspective: The challenge of heterogeneity and the role of antigenic load. Exp Gerontol. 1999, 34: 911-921. 10.1016/S0531-5565(99)00068-6.PubMed
40.
Goronzy JJ, Weyand CM: T cell development and receptor diversity during aging. Curr Opin Immunol. 2005, 17: 468-475.PubMed
41.
Swain S, Clise-Dwyer K, Haynes L: Homeostasis and the age-associated defect of CD4 T cells. Semin Immunol. 2005, 17: 370-377. 10.1016/j.smim.2005.05.007.PubMedCentralPubMed
42.
Kovaiou RD, Weiskirchner I, Keller M, Pfister G, Cioca DP, Grubeck-Loebensten B: Age-related differences in phenotype and function of CD4+ T cells are due to a phenotypic shift from naive to memory effector CD4+ T cells. Int Immunol. 2005, 17: 1359-1366. 10.1093/intimm/dxh314.PubMed
43.
Haynes L, Eaton SM, Burns EM, Randall TD, Swain SL: Newly generated CD4 T cells in aged animals do not exhibit age-related defects in response to antigen. J Exp Med. 2005, 201: 845-851. 10.1084/jem.20041933.PubMedCentralPubMed
44.
Kang I, Hong MS, Nolasco H, Park SH, Dan JM, Choi JY, Craft Kang I: Age-associated change in the frequency of memory CD4+ T cells impairs long term CD4+ T cell responses to influenza vaccine. J Immunol. 2004, 173: 673-681.PubMed
45.
Almanzar G, Schwaiger S, Jenewein B, Keller M, Herndler-Brandstetter D, Wurzner R, Schonitzer D, Grubeck-Lobenstein B: Long-term cytomegalovirus infection leads to significant changes in the composition of the CD8+ T-cell repertoire, which may be the basis for an imbalance in the cytokine production profile in elderly persons. J Virol. 2005, 79: 3675-3683. 10.1128/JVI.79.6.3675-3683.2005.PubMedCentralPubMed
46.
Azuma M, Phillips JH, Lanier LL: CD28- T lymphocytes. antigenic and functional properties. J Immunol. 1993, 150: 1147-1159.PubMed
47.
Effros RB, Dagarag M, Spaulding C, Man J: The role of CD8+ T-cell replicative senescence in human aging. Immunol Rev. 2005, 205: 147-157. 10.1111/j.0105-2896.2005.00259.x.PubMed
48.
Tarazona R, DelaRosa O, Alonso C, Ostos B, Espejo J, Pena J, Solana R: Increased expression of NK cell markers on T lymphocytes in aging and chronic activation of the immune system reflects the accumulation of effector/senescent T cells. Mech Ageing Dev. 2000, 121: 77-88. 10.1016/S0047-6374(00)00199-8.PubMed
49.
Pawelec G, Akbar A, Caruso C, Solana R, Grubeck-Loebenstein B, Wikby A, Pawelec G: Human immunosenescence: Is it infectious?. Immunol Rev. 2005, 205: 257-268. 10.1111/j.0105-2896.2005.00271.x.PubMed
50.
Fann M, Chiu WK, Wood WH, Levine BL, Becker KG, Weng NP: Gene expression characteristics of CD28null memory phenotype CD8+ T cells and its implication in T-cell aging. Immunol Rev. 2005, 205: 190-206. 10.1111/j.0105-2896.2005.00262.x.PubMed
51.
Almanzar G, Schwaiger S, Jenewein B, Keller M, Herndler-Brandstetter D, Wurzner R, Schonitzer D, Grubeck-Loebenstein B: Long-term cytomegalovirus infection leads to significant changes in the composition of the CD8+ T-cell repertoire, which may be the basis for an imbalance in the cytokine production profile in elderly persons. J Virol. 2005, 79: 3675-3683. 10.1128/JVI.79.6.3675-3683.2005.PubMedCentralPubMed
52.
Ghia P, Melchers F, Rolink AG: Age-dependent changes in B lymphocyte development in man and mouse. Exp Gerontol. 2000, 35: 159-165. 10.1016/S0531-5565(99)00095-9.PubMed
53.
Szabo P, Shen S, Weksler ME: Age-associated defects in B lymphocyte development. Exp Gerontol. 1999, 34: 431-434. 10.1016/S0531-5565(99)00023-6.PubMed
54.
Weksler ME: Changes in the B-cell repertoire with age. Vaccine. 2000, 18: 1624-1628. 10.1016/S0264-410X(99)00497-1.PubMed
55.
Yang X, Stedra J, Cerny J: Relative contribution of T and B cells to hypermutation and selection of the antibody repertoire in germinal centers of aged mice. J Exp Med. 1996, 183: 959-970. 10.1084/jem.183.3.959.PubMed
56.
Zheng B, Han S, Takahashi Y, Kelsoe G: Immunosenescence and germinal center reaction. Immunol Rev. 1997, 160: 63-77. 10.1111/j.1600-065X.1997.tb01028.x.PubMed
57.
Kraft R, Bachmann M, Bachmann K, Buerki H, Hess MW, Cottier H, Stoner RD: Satisfactory primary tetanus antitoxin responses but markedly reduced germinal centre formation in first draining lymph nodes of ageing mice. Clin Exp Immunol. 1987, 67: 447-453.PubMedCentralPubMed
58.
Franceschi C, Cossarizza A: Introduction: The reshaping of the immune system with age. Int Rev Immunol. 1995, 12: 1-4. 10.3109/08830189509056697.PubMed
59.
Frasca D, Riley RL, Blomberg BB: Humoral immune response and B-cell functions including immunoglobulin class switch are downregulated in aged mice and humans. Semin Immunol. 2005, 17: 378-384. 10.1016/j.smim.2005.05.005.PubMed
60.
Uyemura K, Castle SC, Makinodan T: The frail elderly: Role of dendritic cells in the susceptibility of infection. Mech Ageing Dev. 2002, 123: 955-962. 10.1016/S0047-6374(02)00033-7.PubMed
61.
Perlmutter LS, Scott SA, Barron E, Chui HC: MHC class II-positive microglia in human brain: Association with alzheimer lesions. J Neurosci Res. 1992, 33: 549-558. 10.1002/jnr.490330407.PubMed
62.
O'Brien K, Fitzgerald DC, Naiken K, Alugupalli KR, Rostami AM, Gran B: Role of the innate immune system in autoimmune inflammatory demyelination. Curr Med Chem. 2008, 15: 1105-1115. 10.2174/092986708784221458.PubMed
63.
Brehin AC, Mouries J, Frenkiel MP, Dadaglio G, Despres P, Lafon M, Couderc T: Dynamics of immune cell recruitment during west nile encephalitis and identification of a new CD19+B220-BST-2+ leukocyte population. J Immunol. 2008, 180: 6760-6767.PubMed
64.
Herrero C, Marques L, Lloberas J, Celada A: IFN-gamma-dependent transcription of MHC class II IA is impaired in macrophages from aged mice. J Clin Invest. 2001, 107: 485-493. 10.1172/JCI11696.PubMedCentralPubMed
65.
Plowden J, Renshaw-Hoelscher M, Engleman C, Katz J, Sambhara S: Innate immunity in aging: Impact on macrophage function. Aging Cell. 2004, 3: 161-167. 10.1111/j.1474-9728.2004.00102.x.PubMed
66.
Cumberbatch M, Dearman RJ, Kimber I: Influence of ageing on langerhans cell migration in mice: Identification of a putative deficiency of epidermal interleukin-1beta. Immunology. 2002, 105: 466-477. 10.1046/j.1365-2567.2002.01381.x.PubMedCentralPubMed
67.
Tan J, Town T, Crawford F, Mori T, DelleDonne A, Crescentini R, Obregon D, Flavell RA, Mullan MJ: Role of CD40 ligand in amyloidosis in transgenic alzheimer's mice. Nat Neurosci. 2002, 5: 1288-1293. 10.1038/nn968.PubMed
68.
Medzhitov R, Janeway C: Innate immunity. N Engl J Med. 2000, 343: 338-344. 10.1056/NEJM200008033430506.PubMed
69.
Krieger M: The other side of scavenger receptors: Pattern recognition for host defense. Curr Opin Lipidol. 1997, 8: 275-280.PubMed
70.
Muzio M, Natoli G, Saccani S, Levrero M, Mantovani A: The human toll signaling pathway: Divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J Exp Med. 1998, 187: 2097-2101. 10.1084/jem.187.12.2097.PubMedCentralPubMed
71.
Guha M, Mackman N: LPS induction of gene expression in human monocytes. Cell Signal. 2001, 13: 85-94. 10.1016/S0898-6568(00)00149-2.PubMed
72.
Fagiolo U, Cossarizza A, Scala E, Fanales-Belasio E, Ortolani C, Cozzi E, Monti D, Franceschi C, Paganelli R: Increased cytokine production in mononuclear cells of healthy elderly people. Eur J Immunol. 1993, 23: 2375-2378. 10.1002/eji.1830230950.PubMed
73.
Ershler WB, Sun WH, Binkley N, Gravenstein S, Volk MJ, Kamoske G, Klopp RG, Roecker EB, Daynes RA, Weindruch R: Interleukin-6 and aging: Blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction. Lymphokine Cytokine Res. 1993, 12: 225-230.PubMed
74.
Clark JA, Peterson TC: Cytokine production and aging: Overproduction of IL-8 in elderly males in response to lipopolysaccharide. Mech Ageing Dev. 1994, 77: 127-139. 10.1016/0047-6374(94)90020-5.PubMed
75.
O'Mahony L, Holland J, Jackson J, Feighery C, Hennessy TP, Mealy K: Quantitative intracellular cytokine measurement: Age-related changes in proinflammatory cytokine production. Clin Exp Immunol. 1998, 113: 213-219. 10.1046/j.1365-2249.1998.00641.x.PubMedCentralPubMed
76.
Roubenoff R, Harris TB, Abad LW, Wilson PW, Dallal GE, Dinarello CA: Monocyte cytokine production in an elderly population: Effect of age and inflammation. J Gerontol A Biol Sci Med Sci. 1998, 53: M20-6.PubMed
77.
Sadeghi HM, Schnelle JF, Thoma JK, Nishanian P, Fahey JL: Phenotypic and functional characteristics of circulating monocytes of elderly persons. Exp Gerontol. 1999, 34: 959-970. 10.1016/S0531-5565(99)00065-0.PubMed
78.
Hasegawa Y, Sawada M, Ozaki N, Inagaki T, Suzumura A: Increased soluble tumor necrosis factor receptor levels in the serum of elderly people. Gerontology. 2000, 46: 185-188. 10.1159/000022157.PubMed
79.
Mariani E, Meneghetti A, Neri S, Ravaglia G, Forti P, Cattini L, Facchini A: Chemokine production by natural killer cells from nonagenarians. Eur J Immunol. 2002, 32: 1524-1529. 10.1002/1521-4141(200206)32:6<1524::AID-IMMU1524>3.0.CO;2-E.PubMed
80.
Hayek MG, Mura C, Wu D, Beharka AA, Han SN, Paulson KE, Hwang D, Meydani SN: Enhanced expression of inducible cyclooxygenase with age in murine macrophages. J Immunol. 1997, 159: 2445-2451.PubMed
81.
Saurwein-Teissl M, Lung TL, Marx F, Gschosser C, Asch E, Blasko I, Parson W, Bock G, Schonitzer D, Trannoy E, Grubeck-Loebenstein B: Lack of antibody production following immunization in old age: Association with CD8(+)CD28(-) T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J Immunol. 2002, 168: 5893-5899.PubMed
82.
Bandres E, Merino J, Vazquez B, Inoges S, Moreno C, Subira ML, Sanchez-Ibarrola A: The increase of IFN-gamma production through aging correlates with the expanded CD8(+high)CD28(-)CD57(+) subpopulation. Clin Immunol. 2000, 96: 230-235. 10.1006/clim.2000.4894.PubMed
83.
Sakata-Kaneko S, Wakatsuki Y, Matsunaga Y, Usui T, Kita T: Altered Th1/Th2 commitment in human CD4+ T cells with ageing. Clin Exp Immunol. 2000, 120: 267-273. 10.1046/j.1365-2249.2000.01224.x.PubMedCentralPubMed
84.
Karanfilov CI, Liu B, Fox CC, Lakshmanan RR, Whisler RL: Age-related defects in Th1 and Th2 cytokine production by human T cells can be dissociated from altered frequencies of CD45RA+ and CD45RO+ T cell subsets. Mech Ageing Dev. 1999, 109: 97-112. 10.1016/S0047-6374(99)00030-5.PubMed
85.
Mbawuike IN, Acuna CL, Walz KC, Atmar RL, Greenberg SB, Couch RB: Cytokines and impaired CD8+ CTL activity among elderly persons and the enhancing effect of IL-12. Mech Ageing Dev. 1997, 94: 25-39. 10.1016/S0047-6374(96)01855-6.PubMed
86.
Rink L, Cakman I, Kirchner H: Altered cytokine production in the elderly. Mech Ageing Dev. 1998, 102: 199-209. 10.1016/S0047-6374(97)00153-X.PubMed
87.
Bernstein ED, Gardner EM, Abrutyn E, Gross P, Murasko DM: Cytokine production after influenza vaccination in a healthy elderly population. Vaccine. 1998, 16: 1722-1731. 10.1016/S0264-410X(98)00140-6.PubMed
88.
Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA: The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med. 1995, 123: 518-527.PubMed
89.
Nichol KL, Margolis KL, Wuorenma J, von Sternberg T: The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med. 1994, 331: 778-784. 10.1056/NEJM199409223311206.PubMed
90.
Saurwein-Teissl M, Lung TL, Marx F, Gschosser C, Asch E, Blasko I, Parson W, Bock G, Schonitzer D, Trannoy E, Grubeck-Loebenstein B: Lack of antibody production following immunization in old age: Association with CD8(+)CD28(-) T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J Immunol. 2002, 168: 5893-5899.PubMed
91.
McGeer PL, McGeer EG: Anti-inflammatory drugs in the fight against alzheimer's disease. Ann N Y Acad Sci. 1996, 777: 213-220. 10.1111/j.1749-6632.1996.tb34421.x.PubMed
92.
McGeer PL, McGeer EG: The inflammatory response system of brain: Implications for therapy of alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev. 1995, 21: 195-218. 10.1016/0165-0173(95)00011-9.PubMed
93.
Shoenfeld Y, Sherer Y, Harats D: Artherosclerosis as an infectious, inflammatory and autoimmune disease. Trends Immunol. 2001, 22: 293-295. 10.1016/S1471-4906(01)01922-6.PubMed
94.
Nguyen TT, Cho SO, Ban JY, Kim JY, Ju HS, Koh SB, Song KS, Seong YH: Neuroprotective Effect of Sanguisorbae Radix against Oxidative Stress-Induced Brain Damage: in Vitro and in Vivo. Biol Pharm Bull. 2008, 31: 2028-35. 10.1248/bpb.31.2028.PubMed
95.
Smith M, Richey P, Taneda S, Kutty R, Sayre L, Monnier V, Perry G: Advanced Maillard reaction end products, free radicals, and protein oxidation in Alzheimer's disease. Ann N Y Acad Sci. 1994, 738: 447-454.PubMed
96.
Smith M, Sayre L, Monnier V, Perry G: Radical AGEing in Alzheimer's disease. Trends Neurosci. 1995, 18: 172-176. 10.1016/0166-2236(95)93897-7.PubMed
97.
Smith M, Rudnicka-Nawro M, Richey P, Praprotnik D, Mulvihill P, Miller C, Sayre L, Perry G: Carbonyl-related posttranslational modification of neurofilament protein in the neurofibrillary pathology of Alzheimer's disease. J Neurochem. 1995, 64: 2660-2666.PubMed
98.
Smith M, Perry G, Richey P, Sayre L, Anderson V, Beal M, Kowall N: Oxidative damage in Alzheimer's. Nature. 1996, 382: 120-121. 10.1038/382120b0.PubMed
99.
Smith M, Harris P, Sayre L, Perry G: Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci. 1997, 94: 9866-9868. 10.1073/pnas.94.18.9866.PubMedCentralPubMed
100.
Smith M, Richey Harris P, Sayre L, Beckman J, Perry G: Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci. 1997, 17 (8): 2653-2657.PubMed
101.
Cras M, Kawai S, Siedlak P, Mulvihill P, Gambetti D, Lowery P, Gonzalez-DeWhitt B, Perry G: Neuronal and microglial involvement in beta-amyloid protein deposition in Alzheimer's disease. Am J Pathol. 1990, 137: 241-246.PubMedCentralPubMed
102.
Colton C, Gilbert D: Production of superoxide anions by a CNS macrophage, the microglia. FEBS Lett. 1987, 223: 284-288. 10.1016/0014-5793(87)80305-8.PubMed
103.
Good P, Werner P, Hsu A, Olanow C, Perl D: Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol. 1996, 149: 21-28.PubMedCentralPubMed
104.
Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T: Inflammation and alzheimer's disease. Neurobiol Aging. 2000, 21: 383-421. 10.1016/S0197-4580(00)00124-X.PubMedCentralPubMed
105.
Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA: Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol. 2001, 60: 759-67.PubMed
106.
Richartz-Salzburger E, Batra A, Stransky E, Laske C, Kohler N, Bartels M, Buchkremer G, Schott K: Altered lymphocyte distribution in alzheimer's disease. J Psychiatr Res. 2007, 41: 174-178. 10.1016/j.jpsychires.2006.01.010.PubMed
107.
Smith M, Hirai K, Hsiao K, Pappolla M, Harris P, Siedlak S, Tabaton M, Perry G: Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem. 1998, 70: 2212-2215.PubMed
108.
Butterfield A, Poon H, St Clair D, Keller J, Pierce W, Klein J, Markesbery W: Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol Dis. 2006, 22: 223-232. 10.1016/j.nbd.2005.11.002.PubMed
109.
Keller J, Schmitt F, Scheff S, Ding Q, Chen Q, Butterfield D, Markesbery W: Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology. 2005, 64: 1152-1156.PubMed
110.
Butterfield D, Reed T, Perluigi M, De Marco C, Coccia R, Cini C, Sultana R: Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci Lett. 2006, 397: 170-173. 10.1016/j.neulet.2005.12.017.PubMed
111.
Smith M, Kutty R, Richey P, Yan S, Stern D, Chader G, Wiggert B, Petersen R, Perry G: Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am J Pathol. 1994, 145: 42-47.PubMedCentralPubMed
112.
Lue LF, Brachova L, Civin WH, Rogers J: Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of alzheimer's disease neurodegeneration. J Neuropathol Exp Neurol. 1996, 55: 1083-1088.PubMed
113.
Webster S, Lue LF, Brachova L, Tenner AJ, McGeer PL, Terai K, Walker DG, Bradt B, Cooper NR, Rogers J: Molecular and cellular characterization of the membrane attack complex, C5b-9, in alzheimer's disease. Neurobiol Aging. 1997, 18: 415-421. 10.1016/S0197-4580(97)00042-0.PubMed
114.
Blasko I, Knaus G, Weiss E, Kemmler G, Winkler C, Falkensammer G, Griesmacher A, Wurzner R, Marksteiner J, Fuchs D: Cognitive deterioration in alzheimer's disease is accompanied by increase of plasma neopterin. J Psychiatr Res. 2007, 41: 694-701. 10.1016/j.jpsychires.2006.02.001.PubMed
115.
Mrak RE, Griffin WS: Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging. 2005, 26: 349-354. 10.1016/j.neurobiolaging.2004.05.010.PubMed
116.
Blasko I, Stampfer-Kountchev M, Robatscher P, Veerhuis R, Eikelenboom P, Grubeck-Loebenstein B: How chronic inflammation can affect the brain and support the development of alzheimer's disease in old age: The role of microglia and astrocytes. Aging Cell. 2004, 3: 169-176. 10.1111/j.1474-9728.2004.00101.x.PubMed
117.
Franceschi C, Bonafe M: Centenarians as a model for healthy aging. Biochem Soc Trans. 2003, 31: 457-461. 10.1042/BST0310457.PubMed
118.
Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, Panourgia MP, Invidia L, Celani L, Scurti M, Cevenini E, Castellani GC, Salvioli S: Inflammaging and anti-inflammaging: A systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev. 2007, 128: 92-105. 10.1016/j.mad.2006.11.016.PubMed
119.
Mutus B, Rabini RA, Franceschi C, Paolisso G, Rizzo MR, Ragno E, Rappelli A, Braconi M, Mazzanti L: Cellular resistance to homocysteine: A key for longevity. Atherosclerosis. 2000, 152: 527-528. 10.1016/S0021-9150(00)00546-3.PubMed
120.
Rabini RA, Vignini A, Martarelli D, Nanetti L, Salvolini E, Rizzo MR, Ragno E, Paolisso G, Franceschi C, Mazzanti L: Evidence for reduction of pro-atherosclerotic properties in platelets from healthy centenarians. Exp Gerontol. 2003, 38: 367-371. 10.1016/S0531-5565(02)00268-1.PubMed
121.
Nanetti L, Vignini A, Moroni C, Bartolini M, Luzzi S, Provinciali L, Mazzanti L: Peroxynitrite production and NOS expression in astrocytes U373MG incubated with lipoproteins from alzheimer patients. Brain Res. 2005, 1054: 38-44. 10.1016/j.brainres.2005.06.025.PubMed
122.
Nanetti L, Moroni C, Vignini A, Vannini P, Franceschi C, Mazzanti L: Age-related changes on platelet membrane: A study on elderly and centenarian monozygotic twins. Exp Gerontol. 2005, 40: 519-525. 10.1016/j.exger.2005.07.002.PubMed
123.
Kario K, Matsuo T: Relation between sialic acid concentrations and the haemostatic system in the elderly. BMJ. 1993, 306: 1650-1651.PubMedCentralPubMed
124.
Troiano L, Pini G, Petruzzi E, Ognibene A, Franceschi C, Monti D, Masotti G, Cilotti A, Forti G: Evaluation of adrenal function in aging. J Endocrinol Invest. 1999, 22: 74-75.PubMed
125.
Lio D, Scola L, Crivello A, Colonna-Romano G, Candore G, Bonafe M, Cavallone L, Franceschi C, Caruso C: Gender-specific association between -1082 IL-10 promoter polymorphism and longevity. Genes Immun. 2002, 3: 30-33. 10.1038/sj.gene.6363827.PubMed
126.
Lio D, Licastro F, Scola L, Chiappelli M, Grimaldi LM, Crivello A, Colonna-Romano G, Candore G, Franceschi C, Caruso C: Interleukin-10 promoter polymorphism in sporadic alzheimer's disease. Genes Immun. 2003, 4: 234-238. 10.1038/sj.gene.6363964.PubMed
127.
Richartz-Salzburger E, Batra A, Stransky E, Laske C, Kohler N, Bartels M, Buchkremer G, Schott K: Altered lymphocyte distribution in alzheimer's disease. J Psychiatr Res. 2007, 41: 174-178. 10.1016/j.jpsychires.2006.01.010.PubMed
128.
Murr C, Hainz U, Asch E, Berger P, Jenewein B, Saurwein-Teissl M, Grubeck-Loebenstein B, Fuchs D: Association of increased neopterin production with decreased humoral immunity in the elderly. Exp Gerontol. 2003, 38: 583-587. 10.1016/S0531-5565(03)00062-7.PubMed
129.
Wirleitner B, Schroecksnadel K, Winkler C, Fuchs D: Neopterin in HIV-1 infection. Mol Immunol. 2005, 42: 183-194. 10.1016/j.molimm.2004.06.017.PubMed
130.
Blasko I, Knaus G, Weiss E, Kemmler G, Winkler C, Falkensammer G, Griesmacher A, Wurzner R, Marksteiner J, Fuchs D: Cognitive deterioration in alzheimer's disease is accompanied by increase of plasma neopterin. J Psychiatr Res. 2007, 41: 694-701. 10.1016/j.jpsychires.2006.02.001.PubMed
131.
Leblhuber F, Walli J, Demel U, Tilz GP, Widner B, Fuchs D: Increased serum neopterin concentrations in patients with alzheimer's disease. Clin Chem Lab Med. 1999, 37: 429-431. 10.1515/CCLM.1999.070.PubMed
132.
Hull M, Pasinetti GM, Aisen PS: Elevated plasma neopterin levels in alzheimer disease. Alzheimer Dis Assoc Disord. 2000, 14: 228-230. 10.1097/00002093-200010000-00007.PubMed
133.
Ikeda T, Yamamoto K, Takahashi K, Yamada M: Immune system-associated antigens on the surface of peripheral blood lymphocytes in patients with alzheimer's disease. Acta Psychiatr Scand. 1991, 83: 444-448. 10.1111/j.1600-0447.1991.tb05573.x.PubMed
134.
Singh VK: Studies of neuroimmune markers in alzheimer's disease. Mol Neurobiol. 1994, 9: 73-81. 10.1007/BF02816106.PubMed
135.
Skias D, Bania M, Reder AT, Luchins D, Antel JP: Senile dementia of alzheimer's type (SDAT): Reduced T8+-cell-mediated suppressor activity. Neurology. 1985, 35: 1635-1638.PubMed
136.
Singh VK, Fudenberg HH, Brown FR: Immunologic dysfunction: Simultaneous study of alzheimer's and older down's patients. Mech Ageing Dev. 1986, 37: 257-264. 10.1016/0047-6374(86)90043-6.PubMed
137.
Leffell MS, Lumsden L, Steiger WA: An analysis of T lymphocyte subpopulations in patients with alzheimer's disease. J Am Geriatr Soc. 1985, 33: 4-8.PubMed
138.
Shalit F, Sredni B, Brodie C, Kott E, Huberman M: T lymphocyte subpopulations and activation markers correlate with severity of alzheimer's disease. Clin Immunol Immunopathol. 1995, 75: 246-250. 10.1006/clin.1995.1078.PubMed
139.
Trieb K, Ransmayr G, Sgonc R, Lassmann H, Grubeck-Loebenstein B: APP peptides stimulate lymphocyte proliferation in normals, but not in patients with alzheimer's disease. Neurobiol Aging. 1996, 17: 541-547. 10.1016/0197-4580(96)00068-1.PubMed
140.
Singh VK: tudies of neuroimmune markers in alzheimer's disease. Mol Neurobiol. 1994, 9: 73-81. 10.1007/BF02816106.PubMed
141.
Xu J, Hong Y, Shen W, Wang L, Di Q, Zhang Y, Sun Y, Xu W, Hu X: P1–369: The impaired suppression function of peripheral blood CD4+ CD25hi regulatory T cells in patients with Alzheimer's disease. Alz and dementia. 2008, 4: T327-10.1016/j.jalz.2008.05.951.
142.
Schindowski K, Peters J, Gorriz C, Schramm U, Weinandi T, Leutner S, Maurer K, Frolich L, Muller WE, Eckert A: Apoptosis of CD4+ T and natural killer cells in alzheimer's disease. Pharmacopsychiatry. 2006, 39: 220-228. 10.1055/s-2006-954591.PubMed
143.
Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, van Leuven F, Heneka MT: Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci. 2003, 23: 9796-9804.PubMed
144.
Blasko I, Marx F, Steiner E, Hartmann T, Grubeck-Loebenstein B: TNFalpha plus IFNgamma induce the production of alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J. 1999, 13: 63-68.PubMed
145.
Mackic JB, Bading J, Ghiso J, Walker L, Wisniewski T, Frangione B, Zlokovic BV: Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to alzheimer's disease lesions. Vascul Pharmacol. 2002, 38: 303-313. 10.1016/S1537-1891(02)00198-2.PubMed
146.
Zlokovic BV, Deane R, Sallstrom J, Chow N, Miano JM: Neurovascular pathways and alzheimer amyloid beta-peptide. Brain Pathol. 2005, 15: 78-83.PubMed
147.
Zhu X, Lee HG, Perry G, Smith MA: Alzheimer disease, the two-hit hypothesis: an update. Biochim Biophys Acta. 2007, 1772: 494-502.PubMed
148.
Nagy Z, Esiri M, Smith A: Expression of cell division markers in the hippocampus in Alzheimer's disease and other neurodegenerative conditions. Acta Neuropathol (Berl). 1997, 93: 294-300. 10.1007/s004010050617.
149.
McShea A, Harris P, Webster K, Wahl A, Smith M: Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. Am J Pathol. 1997, 150: 1933-1939.PubMedCentralPubMed
150.
Vincent J, Zheng D, Dickson D, Kress Y, Davies P: Mitotic phosphoepitopes precede paired helical filaments in Alzheimer's disease. Neurobiol Aging. 1998, 19: 287-296. 10.1016/S0197-4580(98)00071-2.PubMed
151.
Yang Y, Mufson E, Herrup K: Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J Neurosci. 2003, 23: 2557-2563.PubMed
152.
McGeer PL, Schulzer M, McGeer EG: Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 1996, 47: 425-432.PubMed
153.
Breitner JC, Gau BA, Welsh KA: Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology. 1994, 44: 227-232.PubMed
154.
Breitner JCS, Welsh KA, Helms MJ: Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging. 1995, 16: 523-530. 10.1016/0197-4580(95)00049-K.PubMed
155.
Rogers J, Kirby LC, Hempelman SR: Clinical trial of indomethacin in Alzheimer's disease. Neurology. 1993, 43: 1609-1611.PubMed
156.
Scharf S, Mander A, Ugoni A: A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology. 1999, 53: 197-201.PubMed
157.
Aisen PS, Davis KL, Berg JD: A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology. 2000, 54: 588-593.PubMed
158.
Aisen PS, Schafer KA, Grundman M: Effects of rofecoxib or naproxen versus placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003, 289: 2819-2826. 10.1001/jama.289.21.2819.PubMed
159.
Thal LJ, Ferris SH, Kirby L: A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005, 30: 1204-1215. 10.1038/sj.npp.1300690.PubMed
160.
Group AR, Lyketsos CG, Breitner JC: Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007, 68: 1800-1808. 10.1212/01.wnl.0000260269.93245.d2.
161.
van Gool WA, Weinstein HC, Scheltens PK: Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo- controlled study. Lancet. 2001, 358: 455-460. 10.1016/S0140-6736(01)05623-9.PubMed
162.
Siemers E, Skinner M, Dean R, Gonzales C, Satterwhite J, Farlow M, Ness D, May P: Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol. 2005, 28: 126-132. 10.1097/01.wnf.0000167360.27670.29.PubMed
163.
Siemers E, Quinn J, Kaye J, Farlow M, Porsteinsson A, Tariot P, Zoulnouni P, Galvin J, Holtzman D, Knopman D, Satterwhite J, Gonzales C, Dean R, May P: Effects of a gamma-secretase inhibitor in a randomized study of patients with alzheimers disease. Neurology. 2006, 66: 602-604. 10.1212/01.WNL.0000198762.41312.E1.PubMed
164.
Geerts H: Drug evaluation: (R)-flurbiprofen–an enantiomer of flurbiprofen for the treatment of alzheimer's disease. IDrugs. 2007, 10: 121-133.PubMed
165.
Gómez-Isla T, Blesa R, Boada M, Clarimon J, Del Ser T, Domenech G, Ferro J, Gomez-Anson B, Manubens J, Martinez-Lage J, Munoz D, Pena-Casanova J, Torres F: A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study. Alzheimer Dis Assoc Disord. 2008, 22: 21-29.PubMed
166.
Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P: Immunization with amyloid-beta attenuates alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999, 400: 173-177. 10.1038/22124.PubMed
167.
Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T: Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature medicine. 2000, 6: 916-919. 10.1038/78682.PubMed
168.
Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA: Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008, 372: 216-23. 10.1016/S0140-6736(08)61075-2.PubMed
169.
Koller MF, Mohajeri MH, Huber M, Wollmer MA, Roth Z'graggen BV, Sandmeier E, Moritz E, Tracy J, Nitsch RM, Christen P: Active immunization of mice with an abeta-Hsp70 vaccine. Neurodegener Dis. 2004, 1: 20-28. 10.1159/000076666.PubMed
170.
Frenkel D, Dewachter I, van Leuven F, Solomon B: Reduction of beta-amyloid plaques in brain of transgenic mouse model of alzheimer's disease by EFRH-phage immunization. Vaccine. 2003, 21: 1060-1065. 10.1016/S0264-410X(02)00609-6.PubMed
171.
Hara H, Monsonego A, Yuasa K, Adachi K, Xiao X, Takeda S, Takahashi K, Weiner HL, Tabira T: Development of a safe oral abeta vaccine using recombinant adeno-associated virus vector for alzheimer's disease. J Alzheimers Dis. 2004, 6: 483-488.PubMed
172.
Zhang J, Wu X, Qin C, Qi J, Ma S, Zhang H, Kong Q, Chen D, Ba D, He W: A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of alzheimer's disease. Neurobiol Dis. 2003, 14: 365-379. 10.1016/j.nbd.2003.07.005.PubMed
173.
Furlan R, Brambilla E, Sanvito F, Roccatagliata L, Olivieri S, Bergami A, Pluchino S, Uccelli A, Comi G, Martino G: Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain. 2003, 126: 285-291. 10.1093/brain/awg031.PubMed
174.
Nikolic WV, Bai Y, Obregon D, Hou H, Mori T, Zeng J, Ehrhart J, Shytle RD, Giunta B, Morgan D, Town T, Tan J: Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage. Proc Natl Acad Sci USA. 2007, 104: 2507-2512. 10.1073/pnas.0609377104.PubMedCentralPubMed
175.
Town T, Vendrame M, Patel A, Poetter D, DelleDonne A, Mori T, Smeed R, Crawford F, Klein T, Tan J, Mullan M: Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's beta-amyloid(1–42). Reduced Th1 and enhanced Th2 immunity. J Neuroimmunol. 2002, 132: 49-59. 10.1016/S0165-5728(02)00307-7.PubMed
176.
Town T, Tan J, Sansone N, Obregon D, Klein T, Mullan M: Characterization of murine immunoglobulin G antibodies against human amyloid-beta1–42. Neurosci Lett. 2002, 307: 101-104. 10.1016/S0304-3940(01)01951-6.
177.
DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM: Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 2002, 295: 2264-2267. 10.1126/science.1067568.PubMed
178.
Vendrame M: Anti-inflammatory effects of human cord blood cells in a rat model of stroke. Stem Cells Dev. 2005, 14: 595-604. 10.1089/scd.2005.14.595.PubMed
179.
Vendrame M, Cassady J, Newcomb J, Butler T, Pennypacker KR, Zigova T, Sanberg CD, Sanberg PR, Willing AE: Infusion of human umbilical cord blood cells in a rat model of stroke dose-dependently rescues behavioral deficits and reduces infarct volume. Stroke. 2004, 35: 2390-2395. 10.1161/01.STR.0000141681.06735.9b.PubMed
180.
El-Badri NS, Hakki A, Saporta S, Liang X, Madhusodanan S, Willing AE, Sanberg CD, Sanberg PR: Cord blood mesenchymal stem cells: Potential use in neurological disorders. Stem Cells Dev. 2006, 15: 497-506. 10.1089/scd.2006.15.497.PubMed
181.
Garbuzova-Davis S, Gografe SJ, Sanberg CD, Willing AE, Saporta S, Cameron DF, Desjarlais T, Daily J, Kuzmin-Nichols N, Chamizo W, Klasko SK, Sanberg PR: Maternal transplantation of human umbilical cord blood cells provides prenatal therapy in sanfilippo type B mouse model. FASEB J. 2006, 20: 485-487.PubMed
182.
Henning SM, Aronson W, Niu Y, Conde F, Lee NH, Seeram NP, Lee RP, Lu J, Harris DM, Moro A, Hong J, Pak-Shan L, Barnard RJ, Ziaee HG, Csathy G, Go VL, Wang H, Heber D: Tea polyphenols and theaflavins are present in prostate tissue of humans and mice after green and black tea consumption. J Nutr. 2006, 136: 1839-1843.PubMed
183.
Nikolic WV, Hou H, Town T, Zhu Y, Giunta B, Sanberg CD, Zeng J, Luo D, Ehrhart J, Mori T, Sanberg PR, Tan J: Peripherally administered human umbilical cord blood cells reduce parenchymal and vascular beta-amyloid deposits in alzheimer mice. Stem Cells Dev. 2008
184.
Tan J, Town T, Paris D, Placzek A, Parker T, Crawford F, Yu H, Humphrey J, Mullan M: Activation of microglial cells by the CD40 pathway: Relevance to multiple sclerosis. J Neuroimmunol. 1999, 97: 77-85. 10.1016/S0165-5728(99)00053-3.PubMed
185.
Tan J, Town T, Saxe M, Paris D, Wu Y, Mullan M: Ligation of microglial CD40 results in p44/42 mitogen-activated protein kinase-dependent TNF-alpha production that is opposed by TGF-beta 1 and IL-10. J Immunol. 1999, 163: 6614-6621.PubMed
186.
Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, Mattson MP, Flavell RA, Mullan M: Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science. 1999, 286: 2352-2355. 10.1126/science.286.5448.2352.PubMed
187.
Nguyen VT, Walker WS, Benveniste EN: Post-transcriptional inhibition of CD40 gene expression in microglia by transforming growth factor-beta. Eur J Immunol. 1998, 28: 2537-2548. 10.1002/(SICI)1521-4141(199808)28:08<2537::AID-IMMU2537>3.0.CO;2-1.PubMed
188.
Carson MJ, Reilly CR, Sutcliffe JG, Lo D: Mature microglia resemble immature antigen-presenting cells. Glia. 1998, 22: 72-85. 10.1002/(SICI)1098-1136(199801)22:1<72::AID-GLIA7>3.0.CO;2-A.PubMed
189.
Gerritse K, Laman JD, Noelle RJ, Aruffo A, Ledbetter JA, Boersma WJ, Claassen E: CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA. 1996, 93: 2499-2504. 10.1073/pnas.93.6.2499.PubMedCentralPubMed
190.
Desideri G, Cipollone F, Necozione S, Marini C, Lechiara MC, Taglieri G, Zuliani G, Fellin R, Mezzetti A, di Orio F, Ferri C: Enhanced soluble CD40 ligand and alzheimer's disease: Evidence of a possible pathogenetic role. Neurobiol Aging. 2008, 29: 348-356. 10.1016/j.neurobiolaging.2006.10.019.PubMed
191.
Marambaud P, Zhao H, Davies P: Resveratrol promotes clearance of alzheimer's disease amyloid-beta peptides. J Biol Chem. 2005, 280: 37377-37382. 10.1074/jbc.M508246200.PubMed
192.
Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D, Ehrhart J, Townsend K, Zeng J, Morgan D, Hardy J, Town T, Tan J: Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in alzheimer transgenic mice. J Neurosci. 2005, 25: 8807-8814. 10.1523/JNEUROSCI.1521-05.2005.PubMed
193.
Obregon DF, Rezai-Zadeh K, Bai Y, Sun N, Hou H, Ehrhart J, Zeng J, Mori T, Arendash GW, Shytle D, Town T, Tan J: ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced alpha-secretase cleavage of amyloid precursor protein. J Biol Chem. 2006, 281: 16419-16427. 10.1074/jbc.M600617200.PubMed
194.
Giunta B, Obregon D, Hou H, Zeng J, Sun N, Nikolic V, Ehrhart J, Shytle D, Fernandez F, Tan J: EGCG mitigates neurotoxicity mediated by HIV-1 proteins gp120 and tat in the presence of IFN-gamma: Role of JAK/STAT1 signaling and implications for HIV-associated dementia. Brain Res. 2006, 1123: 216-225. 10.1016/j.brainres.2006.09.057.PubMedCentralPubMed
195.
Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM: Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005, 280: 5892-5901. 10.1074/jbc.M404751200.PubMed
196.
Beecher GR: Overview of dietary flavonoids: Nomenclature, occurrence and intake. J Nutr. 2003, 133: 3248S-3254S.PubMed
197.
Hashimoto F, Ono M, Masuoka C, Ito Y, Sakata Y, Shimizu K, Nonaka G, Nishioka I, Nohara T: Evaluation of the anti-oxidative effect (in vitro) of tea polyphenols. Biosci Biotechnol Biochem. 2003, 67: 396-401. 10.1271/bbb.67.396.PubMed
198.
Bors W, Saran M: Radical scavenging by flavonoid antioxidants. Free Radic Res Commun. 1987, 2: 289-294. 10.3109/10715768709065294.PubMed
199.
Zheng LT, Ock J, Kwon BM, Suk K: Suppressive effects of flavonoid fisetin on lipopolysaccharide-induced microglial activation and neurotoxicity. Int Immunopharmacol. 2008, 8: 484-494. 10.1016/j.intimp.2007.12.012.PubMed
200.
Zheng LT, Ock J, Kwon BM, Suk K: Suppressive effects of flavonoid fisetin on lipopolysaccharide-induced microglial activation and neurotoxicity. Int Immunopharmacol. 2008, 8: 484-494. 10.1016/j.intimp.2007.12.012.PubMed
201.
Kim JS, Jobin C: The flavonoid luteolin prevents lipopolysaccharide-induced NF-kappaB signalling and gene expression by blocking IkappaB kinase activity in intestinal epithelial cells and bone-marrow derived dendritic cells. Immunology. 2005, 115: 375-387. 10.1111/j.1365-2567.2005.02156.x.PubMedCentralPubMed
202.
Kim JY, Kina T, Iwanaga Y, Noguchi H, Matsumura K, Hyon SH: Tea polyphenol inhibits allostimulation in mixed lymphocyte culture. Cell Transplant. 2007, 16: 75-83. 10.3727/000000007783472381.PubMed
203.
Mantena SK, Roy AM, Katiyar SK: Epigallocatechin-3-gallate inhibits photocarcinogenesis through inhibition of angiogenic factors and activation of CD8+ T cells in tumors. Photochem Photobiol. 2005, 81: 1174-1179. 10.1562/2005-04-11-RA-487.PubMed
204.
Kang TH, Lee JH, Song CK, Han HD, Shin BC, Pai SI, Hung CF, Trimble C, Lim JS, Kim TW, Wu TC: Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res. 2007, 67: 802-811. 10.1158/0008-5472.CAN-06-2638.PubMedCentralPubMed
205.
Min K, Yoon WK, Kim SK, Kim BH: Immunosuppressive effect of silibinin in experimental autoimmune encephalomyelitis. Arch Pharm Res. 2007, 30: 1265-1272. 10.1007/BF02977779.PubMed
206.
Watson JL, Ansari S, Cameron H, Wang A, Akhtar M, McKay DM: Green tea polyphenol (-)-epigallocatechin gallate blocks epithelial barrier dysfunction provoked by IFN-gamma but not by IL-4. Am J Physiol Gastrointest Liver Physiol. 2004, 287: G954-961. 10.1152/ajpgi.00302.2003.PubMed
207.
Ahn HY, Xu Y, Davidge ST: Epigallocatechin-3-O-gallate inhibits TNFalpha-induced monocyte chemotactic protein-1 production from vascular endothelial cells. Life Sci. 2008, 82: 964-968. 10.1016/j.lfs.2008.02.018.PubMed
208.
Xu Z, Chen S, Li X, Luo G, Li L, Le W: Neuroprotective effects of (-)-epigallocatechin-3-gallate in a transgenic mouse model of amyotrophic lateral sclerosis. Neurochem Res. 2006, 31: 1263-1269. 10.1007/s11064-006-9166-z.PubMed
209.
Graff JC, Jutila MA: Differential regulation of CD11b on gammadelta T cells and monocytes in response to unripe apple polyphenols. J Leukoc Biol. 2007, 82: 603-607. 10.1189/jlb.0207125.PubMed
210.
Yoneyama S, Kawai K, Tsuno NH, Okaji Y, Asakage M, Tsuchiya T, Yamada J, Sunami E, Osada T, Kitayama J, Takahashi K, Nagawa H: Epigallocatechin gallate affects human dendritic cell differentiation and maturation. J Allergy Clin Immunol. 2008, 121: 209-214. 10.1016/j.jaci.2007.08.026.PubMed
211.
Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G: Correlative memory deficits, abeta elevation, and amyloid plaques in transgenic mice. Science. 1996, 274: 99-102. 10.1126/science.274.5284.99.PubMed
212.
Rezai-Zadeh K, Shytle RD, Bai Y, Tian J, Hou H, Mori T, Zeng J, Obregon D, Town T, Tan J: Flavonoid-mediated presenilin-1 phosphorylation reduces alzheimer's disease beta-amyloid production. J Cell Mol Med. 2008
213.
Hyun SK, Jung HA, Chung HY, Choi JS: In vitro peroxynitrite scavenging activity of 6-hydroxykynurenic acid and other flavonoids from gingko biloba yellow leaves. Arch Pharm Res. 2006, 29: 1074-1079. 10.1007/BF02969294.PubMed
214.
Horvathova K, Novotny L, Tothova D, Vachalkova A: Determination of free radical scavenging activity of quercetin, rutin, luteolin and apigenin in H2O2-treated human ML cells K562. Neoplasma. 2004, 51: 395-399.PubMed
215.
Hougee S, Sanders A, Faber J, Graus YM, Berg van den WB, Garssen J, Smit HF, Hoijer MA: Decreased pro-inflammatory cytokine production by LPS-stimulated PBMC upon in vitro incubation with the flavonoids apigenin, luteolin or chrysin, due to selective elimination of monocytes/macrophages. Biochem Pharmacol. 2005, 69: 241-248. 10.1016/j.bcp.2004.10.002.PubMed
216.
Verbeek R, Plomp AC, van Tol EA, van Noort JM: The flavones luteolin and apigenin inhibit in vitro antigen-specific proliferation and interferon-gamma production by murine and human autoimmune T cells. Biochem Pharmacol. 2004, 68: 621-629. 10.1016/j.bcp.2004.05.012.PubMed
217.
Hirano T, Higa S, Arimitsu J, Naka T, Ogata A, Shima Y, Fujimoto M, Yamadori T, Ohkawara T, Kuwabara Y, Kawai M, Matsuda H, Yoshikawa M, Maezaki N, Tanaka T, Kawase I, Tanaka T: Luteolin, a flavonoid, inhibits AP-1 activation by basophils. Biochem Biophys Res Commun. 2006, 340: 1-7.PubMed
218.
Hirano T, Higa S, Arimitsu J, Naka T, Shima Y, Ohshima S, Fujimoto M, Yamadori T, Kawase I, Tanaka T: Flavonoids such as luteolin, fisetin and apigenin are inhibitors of interleukin-4 and interleukin-13 production by activated human basophils. Int Arch Allergy Immunol. 2004, 134: 135-140. 10.1159/000078498.PubMed
219.
Hirata Y, Masuda Y, Kakutani H, Higuchi T, Takada K, Ito A, Nakagawa Y, Ishii H: Sp1 is an essential transcription factor for LPS-induced tissue factor expression in THP-1 monocytic cells, and nobiletin represses the expression through inhibition of NF-kappaB, AP-1, and Sp1 activation. Biochem Pharmacol. 2008, 75: 1504-1514. 10.1016/j.bcp.2007.12.019.PubMed
220.
Zheng LT, Ock J, Kwon BM, Suk K: Suppressive effects of flavonoid fisetin on lipopolysaccharide-induced microglial activation and neurotoxicity. Int Immunopharmacol. 2008, 8: 484-494. 10.1016/j.intimp.2007.12.012.PubMed
221.
Kim JS, Jobin C: The flavonoid luteolin prevents lipopolysaccharide-induced NF-kappaB signalling and gene expression by blocking IkappaB kinase activity in intestinal epithelial cells and bone-marrow derived dendritic cells. Immunology. 2005, 115: 375-387. 10.1111/j.1365-2567.2005.02156.x.PubMedCentralPubMed
222.
Goyarzu P, Malin DH, Lau FC, Taglialatela G, Moon WD, Jennings R, Moy E, Moy D, Lippold S, Shukitt-Hale B, Joseph JA: Blueberry supplemented diet: Effects on object recognition memory and nuclear factor-kappa B levels in aged rats. Nutr Neurosci. 2004, 7: 75-83. 10.1080/10284150410001710410.PubMed
223.
Joseph JA, Denisova NA, Arendash G, Gordon M, Diamond D, Shukitt-Hale B, Morgan D: Blueberry supplementation enhances signaling and prevents behavioral deficits in an alzheimer disease model. Nutr Neurosci. 2003, 6: 153-162. 10.1080/1028415031000111282.PubMed
224.
Obregon DF, Rezai-Zadeh K, Bai Y, Sun N, Hou H, Ehrhart J, Zeng J, Mori T, Arendash GW, Shytle D, Town T, Tan J: ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced alpha-secretase cleavage of amyloid precursor protein. J Biol Chem. 2006, 281: 16419-16427. 10.1074/jbc.M600617200.PubMed
225.
Joseph JA, Shukitt-Hale B, Denisova NA, Bielinski D, Martin A, McEwen JJ, Bickford PC: Reversals of age-related declines in neuronal signal transduction, cognitive, and motor behavioral deficits with blueberry, spinach, or strawberry dietary supplementation. J Neurosci. 1999, 19: 8114-8121.PubMed
226.
Laurin D, Masaki KH, Foley DJ, White LR, Launer LJ: Midlife dietary intake of antioxidants and risk of late-life incident dementia: The honolulu-asia aging study. Am J Epidemiol. 2004, 159: 959-967. 10.1093/aje/kwh124.PubMed
227.
White LR, Petrovitch H, Ross GW, Masaki K, Hardman J, Nelson J, Davis D, Markesbery W: Brain aging and midlife tofu consumption. J Am Coll Nutr. 2000, 19: 242-255.PubMed
228.
Engelhart MJ, Geerlings MI, Ruitenberg A, van Swieten JC, Hofman A, Witteman JC, Breteler MM: Dietary intake of antioxidants and risk of alzheimer disease. JAMA. 2002, 287: 3223-3229. 10.1001/jama.287.24.3223.PubMed
229.
Commenges D, Scotet V, Renaud S, Jacqmin-Gadda H, Barberger-Gateau P, Dartigues JF: Intake of flavonoids and risk of dementia. Eur J Epidemiol. 2000, 16: 357-363. 10.1023/A:1007614613771.PubMed
Metadata
Title
Inflammaging as a prodrome to Alzheimer's disease
Authors
Brian Giunta
Francisco Fernandez
William V Nikolic
Demian Obregon
Elona Rrapo
Terrence Town
Jun Tan
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2008
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/1742-2094-5-51

Other articles of this Issue 1/2008

Journal of Neuroinflammation 1/2008 Go to the issue

Research

Plaque complement activation and cognitive loss in Alzheimer's disease

Short report

Complement anaphylatoxin C5a neuroprotects through regulation of glutamate receptor subunit 2 in vitro and in vivo

Research

Persisting atypical and cystic forms of Borrelia burgdorferiand local inflammation in Lyme neuroborreliosis

Research

Delayed administration of a matrix metalloproteinase inhibitor limits progressive brain injury after hypoxia-ischemia in the neonatal rat

Research

Mannan-Abeta28conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice

Research

Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease